NCT06038617View on ClinicalTrials.gov

Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

PHASE4CompletedINTERVENTIONAL
Enrollment

344

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

April 24, 2025

Study Completion Date

July 25, 2025

Conditions
Fever After VaccinationFeverSeizures Fever
Interventions
BIOLOGICAL

mRNA COVID-19 Vaccine

ACIP Recommended Vaccine

BIOLOGICAL

Routine Childhood Vaccinations

ACIP Recommended Vaccines

Trial Locations (5)

10027

Columbia University, New York

27710

Duke University, Durham

30333

Centers for Disease Control and Prevention, Atlanta

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

94612

Kaiser Permanente Northern California, Oakland

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Kaiser Permanente

OTHER

collaborator

Columbia University

OTHER

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

collaborator

Centers for Disease Control and Prevention

FED

lead

Duke University

OTHER

NCT06038617 - Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children | Biotech Hunter | Biotech Hunter